by Carly Helfand |
And just because pharma may be moving more slowly than other industries doesn’t mean it’s shying away. On the contrary, Harel said, CytoReason—which will present as part of the AI and Digital Health tracks next month at the MIXiii BIOMED conference in Tel Aviv—has seen “most large pharma companies very open” to new technologies.
Source: https://www.fiercepharma.com/marketing/if-pharma-looks-slow-to-adopt-ai-there-s-good-reason-expert